Tickers

1. Composite Trajectory Verdict

For a pre-revenue clinical-stage biotechnology company, the cash flow statement and balance sheet carry the most weight because they determine the runway to reach potential commercialization, while the income statement primarily reflects the pace of R&D investment.

Composite Trajectory: Mixed

The income statement and cash flow statement show deteriorating trends with accelerating net losses (from $402.3M in FY2023 to $766.6M in FY2025, and six-month loss doubling from $307.3M to $604.9M YoY) and increasing operating cash burn (from -$296.8M in FY2023 to -$655.6M in FY2025, and -$287.4M to -$513.1M for six months ended June 30 YoY). The balance sheet shows a mixed picture: cash, cash equivalents and investments declined from $3.13B at December 31, 2024 to $2.44B at December 31, 2025 (10-K, Fair Value Measurements), but rose to approximately $2.5B by June 30, 2026 after a $601.8M net proceeds follow-on offering (10-Q 2026-06-30, Cash Flows). Stockholders' equity fell from $3.31B to $2.69B over 2025 due to accumulated deficit growth (10-K, Consolidated Balance Sheets), while total liabilities increased from $205.5M to $317.2M. The company maintains it has sufficient funds for at least 12 months from each filing date.

2. Red Flags

• Accelerating net losses: FY net loss grew 65% YoY to $766.6M in 2025 (10-K 2025-12-31, Consolidated Statements of Operations); six-month net loss grew 97% YoY to $604.9M (10-Q 2026-06-30, MD&A Results of Operations).
• Escalating operating cash burn: Annual operating cash outflow increased 45% to $655.6M in FY2025 (10-K, Consolidated Statements of Cash Flows); six-month outflow increased 79% to $513.1M (10-Q 2026-06-30, Cash Flows).
• Declining liquid resources (before 2026 raise): Cash, cash equivalents and investments fell 22% from $3.13B (Dec 2024) to $2.44B (Dec 2025) (10-K, Note 3 Fair Value Measurements).
• Growing accumulated deficit: Reached $2.15B at Dec 2025 (10-K, Consolidated Balance Sheets) and $2.8B at June 2026 (10-Q 2026-06-30, MD&A Overview).
• Single-source manufacturing concentration: Relies on Lonza for drug substance and Thermo Fisher for fill-finish; both are single-source suppliers per risk disclosure (10-K, Note 2 Concentration of Credit Risk).
• No revenue generation: Zero product revenue since inception; all funding from equity/pre-funded warrants (10-K, Liquidity and Capital Resources).
• Large non-cancelable purchase commitments: $585.2M at Dec 2025 (10-K, Note 7), increasing to $670.2M at June 2026 (10-Q 2026-06-30, Contractual Obligations), with $394.2M due in remainder of 2026.

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Deteriorating

Net loss increased each full year: $402.3M (FY2023) → $463.9M (FY2024) → $766.6M (FY2025) (10-K 2025-12-31, Consolidated Statements of Operations). Research and development expense drove the increase, rising from $332.3M to $476.6M to $794.3M over the same periods, with external costs (manufacturing, clinical trials) growing from $262.0M to $349.5M to $600.7M (10-K, MD&A Research and Development Expenses). General and administrative expense rose from $60.7M to $92.9M to $129.4M (10-K, Consolidated Statements of Operations). Six-month comparison shows net loss of $604.9M for H1 2026 vs $307.3M for H1 2025, with R&D of $580.6M vs $342.3M and G&A of $68.0M vs $64.7M (10-Q 2026-06-30, MD&A Results of Operations). Net loss per share widened from -$4.14 (FY2023) to -$3.80 (FY2024) to -$5.63 (FY2025) (10-K, Consolidated Statements of Operations). Interest income partially offset losses, growing from $62.9M to $110.0M to $119.7M (10-K, Consolidated Statements of Operations), but other income swung from $2.9M gain to -$4.4M to $37.3M gain due to foreign currency effects.

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Deteriorating

Operating cash outflows increased substantially each year: -$296.8M (FY2023) → -$452.6M (FY2024) → -$655.6M (FY2025) (10-K 2025-12-31, Consolidated Statements of Cash Flows). The six-month outflow nearly doubled: -$287.4M (H1 2025) → -$513.1M (H1 2026) (10-Q 2026-06-30, Cash Flows). Investing cash flow was negative in FY2023 (-$773.3M) and FY2024 (-$2,005.7M) due to large investment purchases, but turned positive in FY2025 (+$437.4M) as maturities and sales exceeded purchases (10-K, Consolidated Statements of Cash Flows). Financing cash flow provided the primary funding: +$639.8M (FY2023), +$2,448.5M (FY2024), but only +$2.0M in FY2025 as no follow-on offerings occurred that year (10-K, Consolidated Statements of Cash Flows). In H1 2026, financing provided +$607.3M, driven by the February 2026 offering's $601.8M net proceeds (10-Q 2026-06-30, Cash Flows). Cash and cash equivalents alone declined from $397.5M (Dec 2023) to $387.9M (Dec 2024) to $174.0M (Dec 2025) (10-K, Consolidated Balance Sheets), then rose to $183.2M at June 30, 2026 (10-Q 2026-06-30, Consolidated Balance Sheets).

5. Balance Sheet Assessment

Balance Sheet Trajectory: Mixed

Total assets decreased from $3.51B (Dec 2024) to $3.00B (Dec 2025) (10-K 2025-12-31, Consolidated Balance Sheets), then increased to $3.14B (June 2026) (10-Q 2026-06-30, Consolidated Balance Sheets). Cash, cash equivalents and investments peaked at $3.13B (Dec 2024), fell to $2.44B (Dec 2025) (10-K, Note 3), and recovered to ~$2.5B (June 2026) after the February offering (10-Q 2026-06-30, MD&A Overview). Total liabilities grew from $205.5M to $317.2M (Dec 2024 to Dec 2025) and to $380.2M (June 2026), driven by accrued contract manufacturing expenses ($36.2M → $74.7M → $125.3M) and accounts payable ($48.5M → $70.9M → $100.9M) (10-K and 10-Q 2026-06-30, Consolidated Balance Sheets). Stockholders' equity declined from $3.31B to $2.69B (Dec 2024 to Dec 2025) due to the $766.6M net loss, then rose to $2.76B (June 2026) after the $601.8M equity raise (10-Q 2026-06-30, Consolidated Balance Sheets). Accumulated deficit grew from -$1.39B to -$2.15B to -$2.8B (10-K and 10-Q 2026-06-30, MD&A Overview). Operating lease liabilities increased from $71.1M to $117.5M (Dec 2024 to Dec 2025) to $115.4M (June 2026) (10-K and 10-Q 2026-06-30, Consolidated Balance Sheets). No debt is reported.

6. Data Gaps

• Stand-alone quarterly income statements for Q1 2026, Q3 2025, Q4 2025 (only six-month and nine-month aggregates provided in 10-Qs)
• Quarterly cash flow statements for Q1 2026, Q3 2025, Q4 2025 (only six-month and nine-month aggregates provided)
• Revenue breakdown (company has zero revenue; not applicable)
• Debt maturity schedule (no debt reported)
• Segment-level profitability (single reportable segment per 10-K Note 13)
• Comparative quarterly data for Q2 2024 vs Q2 2025 (10-Q 2025-06-30 provides six months ended June 30, 2025 and 2024, but not standalone Q2)